Autoantibodies as potential biomarkers of high grade immune-related adverse events (irAEs) in metastatic melanoma patients treated with check point inhibitors (ICIs)

A. Gandhi; J. Taylor; M. Morici; A. Reid; T. Meniawy; M. A. Khattak; M. Millward; E. S. Gray; P. Zaenker

doi:10.1016/j.annonc.2022.07.162

Autoantibodies as potential biomarkers of high grade immune-related adverse events (irAEs) in metastatic melanoma patients treated with check point inhibitors (ICIs)

A. Gandhi, J. Taylor, M. Morici, A. Reid, T. Meniawy, M. A. Khattak, M. Millward, E. S. Gray, P. Zaenker

Internal Medicine

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S597-S597
Number of pages	1
Journal	Annals of Oncology
Volume	33
Issue number	7
DOIs	https://doi.org/10.1016/j.annonc.2022.07.162
Publication status	Published - Sep 2022
Event	Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) - Duration: 9 Sep 2022 → 13 Sep 2022

Access to Document

10.1016/j.annonc.2022.07.162

Cite this

Gandhi, A., Taylor, J., Morici, M., Reid, A., Meniawy, T., Khattak, M. A., Millward, M., Gray, E. S., & Zaenker, P. (2022). Autoantibodies as potential biomarkers of high grade immune-related adverse events (irAEs) in metastatic melanoma patients treated with check point inhibitors (ICIs). Annals of Oncology, 33(7), S597-S597. https://doi.org/10.1016/j.annonc.2022.07.162

@article{90a1439e3e2f4da6a08b5562aa288c20,

title = "Autoantibodies as potential biomarkers of high grade immune-related adverse events (irAEs) in metastatic melanoma patients treated with check point inhibitors (ICIs)",

author = "A. Gandhi and J. Taylor and M. Morici and A. Reid and T. Meniawy and Khattak, {M. A.} and M. Millward and Gray, {E. S.} and P. Zaenker",

year = "2022",

month = sep,

doi = "10.1016/j.annonc.2022.07.162",

language = "English",

volume = "33",

pages = "S597--S597",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "7",

note = "Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) ; Conference date: 09-09-2022 Through 13-09-2022",

}

Gandhi, A, Taylor, J, Morici, M, Reid, A, Meniawy, T, Khattak, MA, Millward, M, Gray, ES & Zaenker, P 2022, 'Autoantibodies as potential biomarkers of high grade immune-related adverse events (irAEs) in metastatic melanoma patients treated with check point inhibitors (ICIs)', Annals of Oncology, vol. 33, no. 7, pp. S597-S597. https://doi.org/10.1016/j.annonc.2022.07.162

TY - JOUR

T1 - Autoantibodies as potential biomarkers of high grade immune-related adverse events (irAEs) in metastatic melanoma patients treated with check point inhibitors (ICIs)

AU - Gandhi, A.

AU - Taylor, J.

AU - Morici, M.

AU - Reid, A.

AU - Meniawy, T.

AU - Khattak, M. A.

AU - Millward, M.

AU - Gray, E. S.

AU - Zaenker, P.

PY - 2022/9

Y1 - 2022/9

U2 - 10.1016/j.annonc.2022.07.162

DO - 10.1016/j.annonc.2022.07.162

M3 - Abstract/Meeting Abstract

VL - 33

SP - S597-S597

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 7

T2 - Annual Meeting of the European-Society-for-Medical-Oncology (ESMO)

Y2 - 9 September 2022 through 13 September 2022

ER -